**Supplementary Table 1. Hepatocellular carcinoma treatment allocation based on Child-Pugh score**

|  |  |  |
| --- | --- | --- |
| **Treatment** | **Child-Pugh B/C, *n* = 284** | **Child-Pugh A, *n* = 536** |
| Curative  | *n* = 26 (9%)Resection, *n* = 12Ablation ± TACE*,* *n* = 14 | *n* =196 (37%)Resection, *n* = 98Ablation ± TACE, *n* = 98 |
| Noncurative  | *n* = 131 (46%)Intra-arterial procedure-TACE, *n* = 91-Radioembolization, *n* = 1Systemic treatment, *n* = 37(± Radiotherapy, *n* = 2) | *n* = 301 (56%)Intra-arterial procedure-TACE, *n* = 220-Radioembolization, *n* = 2-TACE + Systemic treatment, *n* = 11Systemic treatment, *n* = 68 |
| Supportive care | *n* = 127 (45%) | *n* = 39 (7%) |

Data on 820 HCC patients with cirrhosis. TACE, transarterial chemoembolization.